ArticlemBio2020
GRP78 and Integrins Play Different Roles in Host Cell Invasion during Mucormycosis.
Open access · goldAbstract read
In one paragraph
Article in mBio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.
- Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World.Mycopathologia · 2021Pooled it
- Reduced serum iron levels predict poor prognosis in pulmonary mucormycosis patients: a prospective, case‒control study.Scientific reports · 2025Trial
- GRP78 dysregulation: A proposed molecular mechanism linking the tumor microenvironment to sepsis susceptibility in patients with cancer (Review).International journal of molecular medicine · 2026Review
- GRP78 in viral pneumonia: dual regulatory mechanisms and translational prospects.Clinical and experimental medicine · 2026Review
- An automated workflow for fungal cell counting, cell size and data analysis: enhancing throughput and accuracy with the cell analysis and counting tool using ilastik software (caactus).BMC microbiology · 2026Article
- Molecular Mechanisms of Mucormycosis Pathogenesis: Host-Pathogen Interactions and Immune Evasion.Pathogens (Basel, Switzerland) · 2026Review
- Integrin ß4 is a receptor for emerging fungal pathogens from the genera Lomentospora and Scedosporium.PLoS pathogens · 2026Article
- Clinical Features and Predictive Risk Factors for Prognosis in Invasive Pulmonary Aspergillosis and Pulmonary Mucormycosis.The clinical respiratory journal · 2026Article
- Case report: Fatal hematogenous gastrosplenic mucormycosis in an immunocompetent adult following sigmoid perforation, septic shock, and short-term stress glucocorticoids.Frontiers in fungal biology · 2026Article
- Blood protein thwarts deadly fungal disease.Nature · 2026Article
- Angioinvasion severity and admission GCS predict outcomes in invasive central nervous system fungal infections.Frontiers in cellular and infection microbiology · 2026Article
- Article
- Article
- Cytokine Profile and Oxidative Patterns in Murine Models of Disseminated Infection by Mucorales Species.Pathogens (Basel, Switzerland) · 2025Article
- Future Prospects and Challenges in Mucormycosis Research.Journal of fungi (Basel, Switzerland) · 2025Article
- A comprehensive in vitro and in silico assessment of eugenol glycoconjugates against azole and amphotericin B resistant Rhizopus spp.Molecular biology reports · 2025Article
- Article
- Exploring the therapeutic potential of Thymus vulgaris ethanol extract: a computational screening for antimicrobial compounds against COVID-19 induced mucormycosis.Scientific reports · 2025Article
- Diagnosis and management of invasive fungal infections due to non-Aspergillus moulds.The Journal of antimicrobial chemotherapy · 2025Review
- A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response.Science translational medicine · 2025Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Abdullah AlqarihiDivision of Infectious Diseases, The Lundquist Institute for Biomedical Innovation, Harbor-University of California Los Angeles Medical Center, Torrance, California, USA.
Teclegiorgis GebremariamDivision of Infectious Diseases, The Lundquist Institute for Biomedical Innovation, Harbor-University of California Los Angeles Medical Center, Torrance, California, USA.
Yiyou GuDivision of Infectious Diseases, The Lundquist Institute for Biomedical Innovation, Harbor-University of California Los Angeles Medical Center, Torrance, California, USA.
Marc SwidergallDivision of Infectious Diseases, The Lundquist Institute for Biomedical Innovation, Harbor-University of California Los Angeles Medical Center, Torrance, California, USA.ORCID 0000-0002-5261-6267
Sondus AlkhazrajiDivision of Infectious Diseases, The Lundquist Institute for Biomedical Innovation, Harbor-University of California Los Angeles Medical Center, Torrance, California, USA.
Sameh S M SolimanResearch Institute for Medical and Health Sciences, College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates.
Vincent M BrunoInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.
John E EdwardsDivision of Infectious Diseases, The Lundquist Institute for Biomedical Innovation, Harbor-University of California Los Angeles Medical Center, Torrance, California, USA.
Scott G FillerDivision of Infectious Diseases, The Lundquist Institute for Biomedical Innovation, Harbor-University of California Los Angeles Medical Center, Torrance, California, USA.
Priya UppuluriDivision of Infectious Diseases, The Lundquist Institute for Biomedical Innovation, Harbor-University of California Los Angeles Medical Center, Torrance, California, USA.
Ashraf S IbrahimDivision of Infectious Diseases, The Lundquist Institute for Biomedical Innovation, Harbor-University of California Los Angeles Medical Center, Torrance, California, USA ibrahim@lundquist.org.ORCID 0000-0003-3787-8530
University of California, Los Angeles · USLos Angeles Medical Center · USUniversity of Maryland, Baltimore · USUniversity of Sharjah · AE
Funding
Technology CoreU19AI110820 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI RASKO, DAVID A · 2014 to 2023
$36.5MNovel Toxins and Receptors in Mucormycosis Pathogenesis and TreatmentR01AI063503 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI IBRAHIM, ASHRAF S. · 2006 to 2025
$7.3MEndothelial invasion by yeast-phase CandidaR01AI124566 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI FILLER, SCOTT G, MITCHELL, AARON P · 2016 to 2020
$2.7MTherapeutic targeting of growth factor receptors to treat MucormycosisR01AI141360 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BRUNO, VINCENT MICHAEL · 2019 to 2023
$2.5MTargeting the regulatory mechanism of hyphae to lateral yeast growth as a novel therapeutic approach against candidiasisR01AI141794 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI UPPULURI, PRIYA · 2019 to 2022
$1.5MNovel Candida albicans host receptors during infection and immune responseR00DE026856 · NIDCR · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI SWIDERGALL, MARC · 2019 to 2021
$710kHumanized monoclonal antibodies to treat mucormycosisR43AI138904 · NIAID · VITALEX BIOSCIENCES, LLC · PI IBRAHIM, ASHRAF S., LAZAR, GARY · 2018 to 2019
$600kDevelopment of Immunotherapeutic Strategies to Overcome Neonatal CandidiasisR21HD097480 · NICHD · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI UPPULURI, PRIYA · 2019 to 2020
$446kNIAID NIH HHS R01 AI063503NIAID NIH HHS R01 AI124566NIAID NIH HHS R01 AI141360NIAID NIH HHS R01 AI141794NIAID NIH HHS R43 AI138904NIAID NIH HHS U19 AI110820NICHD NIH HHS R21 HD097480NIDCR NIH HHS R00 DE026856
Abstract
Mucormycosis, caused by
Indexed as
Host-Pathogen InteractionsA549 CellsAlveolar Epithelial CellsAnimalsCell LineDiabetic KetoacidosisEndoplasmic Reticulum Chaperone BiPEpithelial CellsErbB ReceptorsFemaleHeat-Shock ProteinsHumansInvasive Fungal InfectionsMaleMiceMice, Inbred ICREndoplasmic Reticulum Chaperone BiPErbB ReceptorsHeat-Shock ProteinsHSPA5 protein, humanHspa5 protein, mouseintegrin alphavbeta1Receptors, Vitronectincell invasionepithelial cellsGRP78integrin β1micemucormycosisRhizopus
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.